The first Chinese national standards for SARS-CoV-2 neutralizing antibody
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
In order to meet the domestic urgent needs of evaluating the immunogenicity of vaccines and the potency testing of therapeutic antibody products against coronavirus disease 2019 (COVID-19), the first Chinese national standards for SARS-CoV-2 neutralizing antibody were established. The potency and stability of the candidate standards were determined by neutralization assay and accelerated degradation study. The stability studies showed that the standards were stable in the short-term. The collaborative study showed that the candidate standards could reduce the variations in neutralization titers between labs and thus improve comparability of neutralizing antibody measurements. Sample 22 has been approved by the Biological Product Reference Standards Sub-Committee of the National Drug Reference Standards Committee as the first Chinese National Standard for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralizing antibody, with an assigned potency of 1,000 units per milliliter (U/ml). This standard will contribute to the standardized assessment of the quality and efficacy of vaccines and therapeutics for COVID-19 in China.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
---|---|
Enthalten in: |
Vaccine - 39(2021), 28 vom: 23. Juni, Seite 3724-3730 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guan, Lidong [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Neutralizing |
---|
Anmerkungen: |
Date Completed 21.06.2021 Date Revised 21.06.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.vaccine.2021.05.047 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM326079866 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM326079866 | ||
003 | DE-627 | ||
005 | 20231225193820.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2021.05.047 |2 doi | |
028 | 5 | 2 | |a pubmed24n1086.xml |
035 | |a (DE-627)NLM326079866 | ||
035 | |a (NLM)34059373 | ||
035 | |a (PII)S0264-410X(21)00621-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guan, Lidong |e verfasserin |4 aut | |
245 | 1 | 4 | |a The first Chinese national standards for SARS-CoV-2 neutralizing antibody |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 21.06.2021 | ||
500 | |a Date Revised 21.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a In order to meet the domestic urgent needs of evaluating the immunogenicity of vaccines and the potency testing of therapeutic antibody products against coronavirus disease 2019 (COVID-19), the first Chinese national standards for SARS-CoV-2 neutralizing antibody were established. The potency and stability of the candidate standards were determined by neutralization assay and accelerated degradation study. The stability studies showed that the standards were stable in the short-term. The collaborative study showed that the candidate standards could reduce the variations in neutralization titers between labs and thus improve comparability of neutralizing antibody measurements. Sample 22 has been approved by the Biological Product Reference Standards Sub-Committee of the National Drug Reference Standards Committee as the first Chinese National Standard for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralizing antibody, with an assigned potency of 1,000 units per milliliter (U/ml). This standard will contribute to the standardized assessment of the quality and efficacy of vaccines and therapeutics for COVID-19 in China | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Neutralization assay | |
650 | 4 | |a Neutralizing antibody | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Standard | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
700 | 1 | |a Yu, Yuanling |e verfasserin |4 aut | |
700 | 1 | |a Wu, Xiaohong |e verfasserin |4 aut | |
700 | 1 | |a Nie, Jianhui |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Jun |e verfasserin |4 aut | |
700 | 1 | |a Wang, Zejun |e verfasserin |4 aut | |
700 | 1 | |a Li, Na |e verfasserin |4 aut | |
700 | 1 | |a Shi, Rui |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Hui |e verfasserin |4 aut | |
700 | 1 | |a Chen, Hongbo |e verfasserin |4 aut | |
700 | 1 | |a Luo, Chunxia |e verfasserin |4 aut | |
700 | 1 | |a Hu, Yaling |e verfasserin |4 aut | |
700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
700 | 1 | |a Xu, Miao |e verfasserin |4 aut | |
700 | 1 | |a Hou, Jifeng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 39(2021), 28 vom: 23. Juni, Seite 3724-3730 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
773 | 1 | 8 | |g volume:39 |g year:2021 |g number:28 |g day:23 |g month:06 |g pages:3724-3730 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2021.05.047 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 39 |j 2021 |e 28 |b 23 |c 06 |h 3724-3730 |